The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder
Status:
Terminated
Trial end date:
2019-05-30
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to
assess the efficacy and safety of brexpiprazole as adjunctive therapy in the treatment of
Major Depressive Disorder. A total of approximately 1100 subjects will be enrolled into the
single-blind treatment for 6 weeks, and 480 incomplete responders will be randomized to
brexpiprazole (2~3 mg) or placebo in a 1:1 ratio (approximately 240 subjects in each group),
for treatment of 6 weeks.